Research programme: stem cell-based therapies - Kadimastem

Drug Profile

Research programme: stem cell-based therapies - Kadimastem

Alternative Names: Astrocyte cell therapy - Kadimastem; AstroRX; Beta cell therapy - Kadimastem; Human pluripotent stem cell-based therapies - Kadimastem; Islet cell therapy - Kadimastem

Latest Information Update: 24 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kadimastem
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Glial cell modulators; Neurogenesis stimulants; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Type 1 diabetes mellitus

Most Recent Events

  • 21 Jun 2017 Kadimastem receives approval from the Hadassah Hospital to initiate a phase I/II clinical trial for Amyotrophic lateral sclerosis in Israel
  • 16 Mar 2017 Kadimastem has patent protection for its cell based treatment technology in USA
  • 21 Dec 2016 Kadimastem signs a memorandum of understanding with Corestem for stem cel-basedl therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top